tiprankstipranks
Trending News
More News >

SpringWorks Therapeutics downgraded to Neutral from Buy at Guggenheim

Guggenheim downgraded SpringWorks Therapeutics (SWTX) to Neutral from Buy after the company and Merck KGaA (MKKGY) announced a definitive agreement for Merck KGaA to acquire SpringWorks for $47 per share in cash.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue